Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS Metabolomics Workbench ST001610 - GNPS Control (DMSO 0.1%; v/v) and 10 uM DRB18 treated A549 lung cancer cells in vitro for 48 hours

ABSTRACT: Control (DMSO 0.1%; v/v) and 10 M DRB18 were used to treated 5 million A549 lung cancer cells in vitro for 48 hours. The untargeted metabolomics analysis was performed on the cell lysates. The main objective of the study was to determine changes in metabolite abundances in lung cancer after treatment with DRB18, an inhibitor of glucose transporter proteins.

INSTRUMENT(S): 6545 Q-TOF LC/MS

ORGANISM(S): Homo Sapiens

SUBMITTER: Pratik Shriwas

PROVIDER: MSV000086879 | GNPS | Mon Feb 15 19:25:00 GMT 2021

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Similar Datasets

Control (DMSO 0.1%; v/v) and 10 µM DRB18 treated A549 lung cancer cells in vitro for 48 hours

Project description:Control (DMSO 0.1%; v/v) and 10 µM DRB18 were used to treated 5 million A549 lung cancer cells in vitro for 48 hours. The untargeted metabolomics analysis was performed on the cell lysates. The main objective of the study was to determine changes in metabolite abundances in lung cancer after treatment with DRB18, an inhibitor of glucose transporter proteins.

2020-11-08 | ST001610 | MetabolomicsWorkbench

Untargeted Metabolomics analysis of A549 treated with 0.5 mM extracellular ATP and 10 ng/ml TGF-beta

Project description:Control, 0.5 mM extracellular ATP and 10 ng/ml TGF-beta were used to treated 5 million A549 lung cancer cells in vitro for 2, 6 and 12 hours. The untargeted metabolomics analysis was performed on the cell lysates. The main objective of the study was to determine changes in metabolite abundances in lung cancer after treatment with extracellular ATP and TGF-beta (a known EMT inducer).

2021-04-04 | ST001779 | MetabolomicsWorkbench

Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity in Vitro and in Vivo

Project description:The human lung tumor cell line, NCI-H526, was treated with DMSO vehicle control or 0.5 µM of the novel small molecule USP7 inhibitor, USP7-797. At 24 and 48 hour time points, cells were harvested and used for RNA-Seq analysis. In order to identify pathways impacted by USP7 (Ubiquitin Specific Peptidase 7) inhibition, we used RNASeq to profile transcriptomic changes in human lung cancer NCI-H526 cells following treatment with the novel, selective USP7 inhibitor, USP7-797, or control DMSO for 24 or 48 hours. USP7 inhibitor treatment resulted in upregulation of a large number of genes normally silenced by the polycomb repressive complex 2 (PRC2). PRC2, whose components include the proteins EZH2, SUZ12 and EED, trimethylates histone H3 at lysine 27 (H3K27me3). Gene set enrichment analysis showed that the top 10 significantly enriched gene sets are all regulated by this pathway. RNA was extracted from approximately 1 million cells using the Allprep DNA/RNA Mini Kit (Qiagen). Whole transcriptome non-stranded libraries were prepared using the TruSeq RNA Library Prep Kit v2 (Illumina). Sequencing was performed on Illumina NovaSeq using paired-end mode, 200 cycles, targeting 40 million reads per sample.

2020-08-17 | GSE151286 | GEO

TMT-labeled mass spectrometry-based proteomics analysis in NCI-H1581 lung cancer cells upon AZD4547 treatment

Project description:FGFR1-amplified lung cancer cell line NCI-H1581 was treated with FGFR inhibitor AZD4547 (0.1μM) or DMSO vehicle for 24 hours. Then TMT-labeled mass spectrometry-based proteomics was carried out in cell lysates to analyze the differentially expressed proteins between two groups.

2022-10-13 | PXD032227 | Pride

Comparison of transcriptomes between DMSO-5uM and Torin1-5uM treated mouse cumulus-oocyte complexes cultured in vitro for 14h

Project description:We sought to identify the potential specific roles of the MTOR signalling in cumulus cells by comparing the transcriptomes of the Control (treated with the DMSO vehicle) and MTOR-specific inhibitor Torin 1(5uM)-treated cumulus-oocyte complexes that were cultured for 16 hours. We compared the transcriptomes between DMSO- and Torin 1- treated cumulus-oocyte complexes.

2016-08-01 | GSE79862 | GEO

scRNAseq of EGFR-mut PC9 cells control or treated for 24h or 72h with osimertinib

Project description:The experiment investigates transcriptional reponse of EGFR-mut PC9 lung cancer cells following treatment for 24h or 72h with EGFR-inhibitor osimertinib compared to control cells on a single cell level.

2021-07-19 | E-MTAB-9468 | biostudies-arrayexpress

Gene Changes Following in vitro Alectinib Treatment in EML4-ALK Murine NSCLC Cells

Project description:First line treatment for EML4-ALK fusion-positive lung cancer patient is the use of an ALK tyrosine kinase inhibitor (TKI), such as alectinib. While most patients initially respond to this therapy, many patients often develop relapse, and efficacious therapies for patients with relapse disease are limited. To study EML4-ALK fusion-positive lung cancer, novel murine lung cancer cell lines were generated from C57BL/6 mice using an intratracheally injected Adeno-virus that contains Cas9 and guide RNAs for the EML4-ALK translocation, which leads to the development of lung tumors. Cell lines were derived from these tumors. In an effort to better understand how cells respond to alectinib, we treated EML4-ALK-positive murine cell lines (EA1, EA2, and EA3 cells) in vitro for 1-7 days with either 100nM alectinib or DMSO-control. At each time point, RNA was isolated from each condition. RNA was submitted to RNA-seq. Differential analysis on the RNA-seq data was performed to determine and track gene changes over time between control and treated cells. These data will allow us to better develop novel therapeutics to use in conjunction with alectinib when treating EML4-ALK fusion-positive patients.

2022-11-05 | GSE217115 | GEO

Human glioma cells treated with irradiation and/or CCI-779

Project description:Gene expression profiling of human glioma cell line LN-308. Cells were treated with the mTOR inhibitor CCI-779 or irradiated with a single dose of 4 Gy or a combination of both. The objective of this studywas to evaluate CCI-779 as a radio-sensitizing agent and to elucidate the underlying mechanisms. Irradiated, CCI-779-, DMSO- (vehicle control) or combination treated LN-308 samples were hybridized against pooled untreated LN-308 samples as reference (CCI+Irradiation vs. Ref; CCI vs. Ref; DMSO+Irradiation vs Ref; DMSO vs. Ref).Three independent replicates were generated for each treatment and control, respectively.

2011-09-19 | E-GEOD-24232 | biostudies-arrayexpress

Epigenetic regulatory pathways in human leukaemia

Project description:3 acute myeloid leukaemic cell lines and 1 control non-small cell lung cancer cell line were treated for 24h with 2 different doses of the KAT2A inhibitor 3-butyrolactone or DMSO vehicle.

2014-01-07 | E-ERAD-213 | biostudies-arrayexpress

Proximity labeling in Arabidopsis seedlings expressing R-degron-Turbo vs. M-degron-Turbo vs. L-degron-Turbo untreated (DMSO control), treated with 10µM Bortezomib and treated with 1µM Concanamycin A.

Project description:Goal was to identify N-recognins for Arginine and Leucine by comparison of biotinylated proteins from 1 week old whole Arabidopsis seedlings constitutively expressing the bait constructs R-degron-Turbo or L-degron-Turbo. M-degron-Turbo served as a negative control. The plants were treated with 50µM biotin and either the proteasome inhibitor Bortezomib (10µM) or the inhibitor of vacuolar acidification Concanamycin A (1µM) or DMSO one hour before harvest.

2024-04-15 | PXD041610 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data